A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

April 15, 2015

Primary Completion Date

June 29, 2017

Study Completion Date

November 20, 2017

Conditions
Cystitis, InterstitialUlcer
Interventions
DRUG

LiRIS®

LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.

DRUG

LiRIS Placebo

LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy

Trial Locations (19)

14214

Western New York Urology Associates, LLC, Cheektowaga

19107

Philadelphia Urosurgical Associates, Philadelphia

21237

Chesapeake Urology Research Associates, Baltimore

21401

Anne Arundel Urology, P.A., Annapolis

27103

Wake Forest Baptist Health, Winston-Salem

27834

Eastern Urological Associates, PA, Greenville

28207

McKay Urology, Charlotte

30005

Atlanta Medical Research Institute, Alpharetta

44109

MetroHealth System/Center for Advanced Gynecology, Cleveland

48073

Beaumont Health System, Royal Oak

49009

Beyer Research, Kalamazoo

53227

Aurora Health Care, West Allis

63110

Washington University School of Medicine Department of Surgery, St Louis

92562

Tri Valley Urology Medical Group, Murrieta

95688

Sutter Institute for Medical Research, Vacaville

98195

University of Washington, Seattle

06032

Women's Health Specialty Care, Farmington

V8T 2C1

Silverado Research Inc, Victoria

M4N 3M5

Sunnybrook Health Science Centre, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY

NCT02395042 - A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions | Biotech Hunter | Biotech Hunter